vadimezan has been researched along with cyproheptadine in 3 studies
Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (cyproheptadine) | Trials (cyproheptadine) | Recent Studies (post-2010) (cyproheptadine) |
---|---|---|---|---|---|
272 | 16 | 101 | 2,297 | 262 | 201 |
Protein | Taxonomy | vadimezan (IC50) | cyproheptadine (IC50) |
---|---|---|---|
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.0024 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.564 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.035 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.016 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0031 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0038 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.283 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.016 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.164 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0031 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.038 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.275 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.122 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.046 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.158 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.564 | |
Histamine H2 receptor | Homo sapiens (human) | 0.198 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.107 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.001 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0024 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.122 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0031 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0037 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.048 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0094 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.281 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.14 | |
Histone-lysine N-methyltransferase SETD7 | Homo sapiens (human) | 2.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baguley, BC; Cole, G; Li, Z; Thomsen, LL | 1 |
Baguley, BC; Ching, LM; Kestell, P; Philpott, M; Zhao, L; Zhuang, L | 1 |
Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 1 |
3 other study(ies) available for vadimezan and cyproheptadine
Article | Year |
---|---|
Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyproheptadine; Flavonoids; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Necrosis; Nitrates; Nitric Oxide; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1993 |
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyproheptadine; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Female; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Serotonin Antagonists; Tissue Distribution; Xanthenes; Xanthones | 2001 |
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Topics: Animals; Antineoplastic Agents; Cyproheptadine; Diclofenac; Drug Interactions; Glucuronides; Hydroxylation; Male; Mice; Microsomes, Liver; Rats; Rats, Wistar; Thalidomide; Xanthenes; Xanthones | 2001 |